Atlas Trials

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Clinical trial NCT06226883 · RECRUITING

Trial details

NCT number
NCT06226883
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Inflammatory Bowel DiseasesCrohn's Disease
Start date
2024-07-18
Primary completion
2028-09-01
Enrollment
385

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.